Noninvasive | Transdermal Wound Care

(deoxyhemoglobin vasodilator)

Products on this website for prescription (Rx) for U.S. residents.

foot microvessles

closing severe Diabetic wounds in 4-8 weeks*

Advanced Solution.

According to WoundCareCenters.org, a chronic wound is one that has failed to progress through the phases of healing in an orderly and timely fashion and has shown no significant progress toward healing in 30 days. Diabetic foot is one of the most common, costly and severe complications of diabetes.

Amputation in people with diabetes is 10 to 20 times more common than in people without diabetes and it is estimated that every 30 seconds a lower limb or part of a lower limb is lost somewhere in the world as a consequence of diabetes.1

1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017.

Successful multisite and multicountry pivotal human clinical studies with D’OXYVA® (deoxyhemoglobin vasodilator) utilizing pharmaceutical-grade, FDA-cleared, vaporized transdermal carbon dioxide (CO2) has recorded healing and closing chronic diabetic foot ulcers (Wagner 2-3) in 4-8 weeks* on average with an exceptional efficacy and safety profile.










Carbon can hold on to things and let them go, kind of like Velcro (which is made of carbon, as it happens). It makes strong bonds that give molecules such as proteins and drugs their shape, and also readily releases those bonds, letting molecules emit stored energy. And carbon’s ability to maintain four bonds at once makes it the periodic table’s architectural workhorse.

Advanced Transdermal Nerve & Cardiovascular Stimulant

how it works?

D’OXYVA® gently delivers a supersaturated vaporized mixture of FDA-cleared pharmaceutical-grade carbon dioxide on the surface of the skin. The autonomic nervous system’s CO2 skin receptors signal an ischemia-induced state to promote powerful vascular, neurological, and hormonal responses.

D'OXYVA transdermal applicator TQ

the microcirculation is everything

Fast. Powerful. Painless.

systemic & long-term benefits

When seeking advanced wound care treatments regularly, D’OXYVA® significantly improves microcirculation and promotes oxygen-rich, pH-balanced blood flow in the local microvascular bed.

Exceptional Safety & Efficacy

IRB-approved, pivotal human clinical studies with D’OXYVA® have shown extraordinary results for the role of transdermal noninvasive chronic wound treatment using ultra-purified, non-toxic, FDA-cleared pharmaceutical-grade carbon dioxide (CO2), especially when all other approaches failed.

wound closure in 4-8 weeks

In an ongoing multiyear, multicountry, multicenter, randomized pivotal clinical trial on patients with diabetic foot ulcers (Wagner 2-3), D’OXYVA® has demonstrated speeding up diabetic wound healing and ultimately wound closure to an average of 5 weeks.

Latest Breakthroughs

The Blog.

Switch To D'OXYVA®.

The only gentle, rapid, and painless transdermal solution without breaking the layers of the skin.

D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive, simple and effective method of mild to severe chronic wound care. Its fully noninvasive transdermal approach delivers a host of benefits including but not limited to significant blood flow in the microcirculation (perfusion index), oxygen saturation (SpO2), nutrients, nerve stimulation (parasympathetic), which together are crucial for the complete and painless wound healing process.

Get in touch to avail D’OXYVA® for rapid chronic wound treatment.